Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Comparison of detergent‐based decellularization protocols for the removal of antigenic cellular components in porcine aortic valve

Comparison of detergent‐based decellularization protocols for the removal of antigenic cellular... AbbreviationsDAB3,3′‐diaminobenzidineDMEMDulbecco's modified Eagle mediumDWdry weightGAGglycosaminoglycanH&Ehematoxylin and eosinHMWhigh molecular weightLMWlow molecular weightMHCmajor histocompatibility complexPAVporcine aortic valvePBSphosphate‐buffered salinePIpropidium iodideSDsodium deoxycholateSDS‐PAGEsodium dodecyl sulfate‐polyacrylamide gel electrophoresisSDSsodium dodecyl sulfateVICsvalvular interstitial cellsα‐Galgalactose‐α‐1,3 galactoseα‐SMAα‐smooth muscle actinINTRODUCTIONSurgical replacement of diseased heart valves using mechanical or biological prostheses is now commonplace, and it enhances survival and quality of life for many patients. Mechanical prostheses have a functional life span of at least 25 years but require lifelong anticoagulation therapy to minimize risks of thrombosis and embolism. Biological prostheses, especially homografts, have better hemodynamic characteristics and avoid the use of long‐term anticoagulation therapies, but their supply is limited. The use of animal‐derived xenografts is desired as an alternative.Decellularized porcine aortic valve (PAV) exhibits great potential as a valvular scaffold because of its anatomical similarity to human valves. However, in clinical application, decellularized PAVs have been met with varying levels of success, as residual xenoantigenic components within treated PAVs have been found to evoke an adverse immune response. For example, the first commercially available decellularized PAV, SynerGraft (CryoLife), experienced early failure due to adverse immune responses caused by the incomplete decellularization of the sinus and aortic wall components. Therefore, effective removal of antigenic cellular components is an essential step in http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Xenotransplantation Wiley

Comparison of detergent‐based decellularization protocols for the removal of antigenic cellular components in porcine aortic valve

Download PDF
13 pages

Loading next page...
 
/lp/wiley/comparison-of-detergent-based-decellularization-protocols-for-the-VKOA07ghoI

References (54)

Publisher
Wiley
Copyright
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
ISSN
0908-665X
eISSN
1399-3089
DOI
10.1111/xen.12380
pmid
29446183
Publisher site
See Article on Publisher Site

Abstract

AbbreviationsDAB3,3′‐diaminobenzidineDMEMDulbecco's modified Eagle mediumDWdry weightGAGglycosaminoglycanH&Ehematoxylin and eosinHMWhigh molecular weightLMWlow molecular weightMHCmajor histocompatibility complexPAVporcine aortic valvePBSphosphate‐buffered salinePIpropidium iodideSDsodium deoxycholateSDS‐PAGEsodium dodecyl sulfate‐polyacrylamide gel electrophoresisSDSsodium dodecyl sulfateVICsvalvular interstitial cellsα‐Galgalactose‐α‐1,3 galactoseα‐SMAα‐smooth muscle actinINTRODUCTIONSurgical replacement of diseased heart valves using mechanical or biological prostheses is now commonplace, and it enhances survival and quality of life for many patients. Mechanical prostheses have a functional life span of at least 25 years but require lifelong anticoagulation therapy to minimize risks of thrombosis and embolism. Biological prostheses, especially homografts, have better hemodynamic characteristics and avoid the use of long‐term anticoagulation therapies, but their supply is limited. The use of animal‐derived xenografts is desired as an alternative.Decellularized porcine aortic valve (PAV) exhibits great potential as a valvular scaffold because of its anatomical similarity to human valves. However, in clinical application, decellularized PAVs have been met with varying levels of success, as residual xenoantigenic components within treated PAVs have been found to evoke an adverse immune response. For example, the first commercially available decellularized PAV, SynerGraft (CryoLife), experienced early failure due to adverse immune responses caused by the incomplete decellularization of the sinus and aortic wall components. Therefore, effective removal of antigenic cellular components is an essential step in

Journal

Xenotransplantation – Wiley

Published: Jan 1, 2018

Keywords: ; ; ; ;

There are no references for this article.